eCite Digital Repository

Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease

Citation

Eri, RD and Kodumudi, N and Summerlin, D and Srinivasan, M, Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease, Inflammatory Bowel Disease, 14, (4) pp. 458-470. ISSN 1536-4844 (2008) [Refereed Article]

DOI: doi:10.1002/ibd.20344

Abstract

Background: Human inflammatory bowel disease (IBD) is a chronic condition mediated by aberrant immune responses to the luminal antigens by activated CD4+ T cells. The CD80/CD86: CD28/CD152 costimulatory pathways transmit signals critical for T cell activation and suppression. Macrophages and epithelial cells are the chief antigen-presenting cells in the gut. Macrophages from the IBD colon express significantly elevated levels of CD80 and CD86 costimulatory molecules. The CD28-CD80 interaction primarily participates in breaking the tolerance and inducing the immune response in murine models of colitis. Blockade of CD80-costimulatory axis is an attractive strategy in the treatment of IBD. Methods: Incorporating the structural information of the CD80: CD152 complex together with the preferences of interface residues to form polyproline type II helix, we designed novel peptide agents that selectively blocked CD80 receptor interactions. Results: Administration of CD80 blocking agent at the time of adoptive transfer prevented the SCID mice from CD4+CD45Rbhigh T-cell mediated colitis. Significantly, CD80-CAP (competitive antagonist peptide) treatment suppressed established inflammation in TNBS-induced colitis, a model for Th1-mediated Crohn's disease. The colons of the mice receiving the CD80 blocking agent appeared unaffected macroscopically and exhibited negligible microscopic inflammation. The CD80-CAP treatment was associated with significantly reduced Th1 cytokines in the colon. Conclusions: The CD80 blocking peptide appeared to mediate protection against colitis by inducing Th2 skewing of the cytokine response. Copyright © 2008 Crohn's & Colitis Foundation of America, Inc.

Item Details

Item Type:Refereed Article
Research Division:Biological Sciences
Research Group:Genetics
Research Field:Genetic Immunology
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Digestive System Disorders
Author:Eri, RD (Dr Raj Eri)
ID Code:67792
Year Published:2008
Web of Science® Times Cited:20
Deposited By:Health Sciences A
Deposited On:2011-03-08
Last Modified:2011-03-08
Downloads:0

Repository Staff Only: item control page